Hingmire, S., & Raut, N. (2015). Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens. South Asian Journal of Cancer, 4, 7–10. 

To assess the safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting (CINV) prophylaxis with highly emetogenic cheomtherapy (HEC) or moderately emetogenic chemotherapy (MEC) regimens

Patients received 125 mg aprepitant on day 1 and 80 mg along with palonosetron and dexamethasone

• N = 75   
• AGE RANGE = 18-71 years
• MALES: 10.3%, FEMALES: 89.7%
• CURRENT TREATMENT: Chemotherapy
• KEY DISEASE CHARACTERISTICS: Multiple tumor types 
• OTHER KEY SAMPLE CHARACTERISTICS: Sixty percent were receiving HEC therapy.

• SITE: Multi-site   
• SETTING TYPE: Outpatient    
• LOCATION: India

PHASE OF CARE: Active antitumor treatment

Open-label, prospective, observational

• Complete response (CR) defined as no emesis and no use of rescue medicatiton
• Common Terminology Criteria for Adverse Events (CTCAE), version 4

For all regimens, CR rates were 96.8%, 93.7%, and 92% for acute, delayed, and overall phases. Nine percent reported side effects; the most common was hiccoughs.

Triple drug antiemetic prophylaxis was effective to manage CINV in most patients.

• Small sample (< 100)
• Risk of bias (no control group)
• Risk of bias (no blinding)
• Risk of bias (no random assignment)

This study adds to the substantial body of evidence for the efficacy of triple drug antiemetic regimens for the prevention of CINV.